Levodopa in Parkinson’s Disease: Current Status and Future Developments

BACKGROUND: Ever since the pioneering reports in the 60s, L-3,4-Dioxyphenylalanine (levodopa) has represented the gold standard for the treatment of Parkinson’s Disease (PD). However, long-term levodopa (LD) treatment is frequently associated with fluctuations in motor response with serious impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tambasco, Nicola, Romoli, Michele, Calabresi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187751/
https://www.ncbi.nlm.nih.gov/pubmed/28494719
http://dx.doi.org/10.2174/1570159X15666170510143821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187751/
https://www.ncbi.nlm.nih.gov/pubmed/28494719
http://dx.doi.org/10.2174/1570159X15666170510143821

Ejemplares similares